[1] Joensuu H,
Fletcher C,
Dimitrijevic S,
Silberman S,
Roberts P,
Demetri G.
Management of malignant gastrointestinal stromal tumours.
Lancet Oncol 2002; 3: 655-664
[2] Nilsson B,
Bumming P,
Meis-Kindblom JM,
Odén A,
Dortok A,
Gustavsson B,
Sablinska K,
Kindblom LG: Gastrointestinal stromal tumors: the incidence,
prevalence,
clinical course,
and prognostication in the preimatinib mesylate era - a population-based study in western Sweden.
Cancer 2005,
103:821-829.
[3] Heinrich MC,
Corless CL,
Duensing A,
et al.
PDGFRA activating mutations in gastrointestinal stromal tumors.
Science 2003;299:708–710.
[4] Miettinen M,
Majidi M,
Lasota J: Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): A review.
Eur J Cancer 2002,
38: S39-51.
[5] Hong X,
Choi H,
Loyer EM et al.
Gastrointestinal stromal tumor: Role of CT in diagnosis and in response evaluation and surveillance after treatment with imatinib.
Radiographics 2006;26:481–495.
[6] Disease of Abdomen and Pelvis; J.
Hodler,
G.K.
von Schuithess,
Ch.L.
Zollikofer.
Springer ISBN: 978-88-470-1637-8
[7] Choi H.
Response Evaluation of Gastrointestinal Stromal Tumors.
The Oncologist 2008;13(suppl 2):4–7
[8] Choi H,
Charnsangavej C,
Faria S et al.
CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: A quantitative analysis correlated with FDG PET findings.
AJR Am J Roentgenol 2004;183:1619–1628.
[9] Therasse P,
Arbuck SG,
Eisenhauer EA et al.
New guidelines to evaluate the response to treatment in solid tumors.
European Organization for Research and Treatment of Cancer,
National Cancer Institute of the United States,
National Cancer Institute of Canada.
J Natl Cancer Inst 2000;92:205–216.